MedTrace Logo

SENTINEL LYMPH NODE BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY

NCT04250129 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-01-31

No results posted yet for this study

Summary

Omitting axilary lymph node dissection (ALND) following SLNB with residual cancer in patients with locally advanced disease after neoadjuvan chemotherapy (NAC) is still controversial. In this study, the investigators evaluated factors affecting local recurrence and outcome in patients with locally advanced breast cancer (LABC), who underwent sentinel lymph node (SLN) with or without ALND after NAC.

Conditions

  • Sentinel Lymph Node

Sponsors & Collaborators

  • Federation of Breast Diseases Societies

    lead OTHER

Principal Investigators

  • Neslihan Cabioglu, Prof · Istanbul University

  • Hasan Karanlik · Istanbul University Institute of Oncology

  • Guldeniz Karadeniz Cakmak · Bulent Ecevit University Faculty of Medicine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2021-12-31
Completion
2023-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04250129 on ClinicalTrials.gov